Switzerland
  • /
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • People
  • US
  • UK
  • Germany
  • France
  • Africa
  • CH
  • @

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • /
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • People
  • US
  • UK
  • Germany
  • France
  • Africa
  • CH
  • @

Browsing Tag

GuruFocus

30 posts
RRoche
Roche (RHHBY) Reports Q1 Sales Decline Amid Currency Challenges
Read More

Roche (RHHBY) Partners with Defand Therapeutics in $1 Billion On

  • 2026-10-09
On October 08, 2026, Roche Holding AG (OTCPK: RHHBY) announced a strategic partnership with Chinese biotech startup Defand…
RRoche
Roche's $2.3 Billion Nurix Deal Sends Shares Moving
Read More

Roche Stocks: Genentech Commits $100 Million Upfront in Potentia

  • 2026-10-08
Roche Holding, the Swiss pharmaceutical group (RO), committed $100 million upfront through Genentech to license Alector’s experimental Parkinson’s…
RRoche
Roche Drops as Phase 3 Kidney Signal Needs Two-Year Proof
Read More

Roche Drops as Phase 3 Kidney Signal Needs Two-Year Proof

  • 2026-09-30
This article first appeared on GuruFocus. Roche Holding (RHHBY), the pharmaceuticals and diagnostics group, reported that its experimental…
UUBS
PAGS Maintained by UBS -- Price Target Lowered to $11.00
Read More

PAGS Maintained by UBS — Price Target Lowered to $11.00

  • 2026-09-29
On October 23, 2023, PagSeguro Digital PAGS received an updated rating from UBS analyst Kaio Prato, who maintained…
UUBS
CoreWeave Lands Fresh Wall Street Vote of Confidence as UBS Sets $120 Target
Read More

CoreWeave Lands Fresh Wall Street Vote of Confidence as UBS Sets $120 Target

  • 2026-09-24
This article first appeared on GuruFocus. CoreWeave is drawing fresh attention from Wall Street after UBS began covering…
UUBS
CoreWeave Lands Fresh Wall Street Vote of Confidence as UBS Sets
Read More

CoreWeave Lands Fresh Wall Street Vote of Confidence as UBS Sets

  • 2026-09-24
CoreWeave is drawing fresh attention from Wall Street after UBS began covering the AI infrastructure provider with a…
RRoche
Roche Drops as Phase 3 Kidney Signal Needs Two-Year Proof
Read More

Roche Drops as Phase 3 Kidney Signal Needs Two-Year Proof

  • 2026-09-24
This article first appeared on GuruFocus. Roche Holding (RHHBY), the pharmaceuticals and diagnostics group, reported that its experimental…
UUBS
UBS Delivers Bullish Call on 10 Stocks With Up to 62% Upside
Read More

UBS Delivers Bullish Call on 10 Stocks With Up to 62% Upside

  • 2026-09-17
This article first appeared on GuruFocus. UBS has highlighted 10 industrial companies it sees as positioned for a…
NNovartis
Novartis Rebounds as $30 Billion Wipeout Draws Board Challenge
Read More

Novartis Rebounds as $30 Billion Wipeout Draws Board Challenge

  • 2026-09-10
This article first appeared on GuruFocus. Novartis (NYSE:NVS), the Swiss pharmaceutical group, rebounded 0.8% to $138.545 Thursday as…
NNovartis
Novartis Rebounds as $30 Billion Wipeout Draws Board Challenge
Read More

Novartis Rebounds as $30 Billion Wipeout Draws Board Challenge

  • 2026-09-10
This article first appeared on GuruFocus. Novartis (NYSE:NVS), the Swiss pharmaceutical group, rebounded 0.8% to $138.545 Thursday as…
NNovartis
Novartis Crashes 13.5% After $12 Billion Deal's Lead Drug Fails
Read More

Novartis Crashes 13.5% After $12 Billion Deal’s Lead Drug Fails

  • 2026-09-09
This article first appeared on GuruFocus. Novartis (NYSE:NVS), the Swiss pharmaceutical giant, absorbed a brutal setback Tuesday after…
UUBS
UBS Stays Flat After Flipping From Zero Fed Hikes to Two
Read More

UBS Stays Flat After Flipping From Zero Fed Hikes to Two

  • 2026-09-07
This article first appeared on GuruFocus. UBS Group (NYSE:UBS), the global wealth-management and investment-banking powerhouse, flipped its Federal…
Switzerland
www.europesays.com